



# First and only approved therapy for MuSK antibody-positive gMG in the United States

Market Event Summary

Preeti Attri, Ph.D. | July 2024

# Addressing anti-MuSK-positive gMG patients' unmet need

## Background and context

### Rystiggo

In July 2023, UCB launched Rystiggo (rozanolixizumab) in the United States for both anti-AChR- and anti-MuSK-positive gMG. The biologic inhibits FcRn, similar to Argenx's Vyvgart (efgartigimod alfa), although Vyvgart is approved only for anti-AChR-positive gMG.

#### - Marketing advantage

Rystiggo is the first and only drug targeted for MuSK-gMG patients. In 2023, according to a survey of neurologists conducted by Clarivate in 2024, approximately 60% of U.S. respondents prescribed Rystiggo to their MuSK-gMG patients. UCB is helping eligible MG patients start this therapy through its ONWARD support program..

### A contrast: rituximab

- In the absence of targeted therapies, more than 60% of surveyed U.S. respondents prescribe rituximab off-label to their MuSK-gMG patients, likely owing to the drug's efficacy in these patients and their familiarity and comfort prescribing it.

## Clarivate's takeaways



### Are patients' unmet needs being addressed?

All marketed drugs except Rystiggo are approved only for anti-AChR-positive gMG. Given the paucity of targeted drugs, nearly two-thirds of surveyed U.S. respondents treat their MuSK-gMG patients with rituximab. Rystiggo's introduction in the market will eventually address the strong unmet need in the treatment of MuSK-gMG.



### How does Rystiggo impact patients' treatments?

Rystiggo's approval marks a pivotal advance in the treatment of MuSK-gMG. Because no other treatment is approved for this population, Rystiggo could become the standard of care for these patients if real-world data continue to demonstrate strong efficacy and safety.



### Could Rystiggo's approval lead to more targeted MuSK-gMG therapies?

Multiple companies have agents with diverse MOAs in mid- / late-phase development for MG, and more developers have started including MuSK-gMG patients in ongoing clinical trials (e.g., Johnson & Johnson's nipocalimab, Merck Healthcare's oral cladribine, Cartesian Therapeutics' descartes-08). If any of these therapies prove effective, the number of treatment options for MuSK-gMG could increase. Nevertheless, Rystiggo's head start may give it a competitive advantage in the near future.

# About the author



## Preeti Attri, Ph.D.

### Healthcare Research and Data Analyst

Prior to joining Clarivate, Preeti Attri was a business analyst at Smart Analyst (India) Private Limited. She has experience in market assessment, competitive intelligence, primary market research, market forecasting, analogue and indication assessment, disease portfolio optimization, and database research. She received her Ph.D. in cancer epigenetics from the National Institute of Immunology in New Delhi.

[preeti.attri@clarivate.com](mailto:preeti.attri@clarivate.com)

### Clarivate coverage of myasthenia gravis

- Current Treatment: Physician Insights (US), providing insights on medical practice from surveyed physicians.
- Treatment Algorithms: Claims Data Analysis (US), providing details on the treatment journey and brand usage practices based on patient-level claims data.
- Epidemiology, with global coverage of the diagnosed prevalence of MG, as well as subpopulation data in select regions.



# Think forward™

**Have a question?**

healthcare.support@clarivate.com  
clarivate.com

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

#### **About Clarivate**

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://www.clarivate.com)

**© 2024 Clarivate. All rights reserved**

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.